The Oncotype DX® portfolio includes tests for breast and colon cancer, which have helped more than 1 million patients make more informed treatment choices.1 The Oncotype DX Breast Recurrence Score® test delivers critical genomic information that no other genomic test or risk assessment method provides to help guide treatment decisions.2,3
Reason # 1: Genomic testing provides treatment guidance
Genetic tests help people understand their risk of getting cancer. Genomic tests help guide people who have been diagnosed with cancer in choosing an appropriate treatment plan.
Reason # 2: Predictive and prognostic
Only the Oncotype DX Breast Recurrence Score test has predictive and prognostic results you can count on for your early-stage invasive breast cancer patients.4-7
*Predicts the benefit of adding chemotherapy to endocrine therapy.
†Node-negative and postmenopausal, HR positive, HER2 negative breast cancer.
‡Early-stage invasive HR positive, HER2 negative breast cancer.
Reason # 3: Goes beyond clinicopathological factors
Traditionally, breast cancer treatment was based only on clinicopathological factors, which provide risk estimates for a patient population. The Breast Recurrence Score® test goes beyond traditional assessment methods, using genomic insights to provide individualized information about the estimated risk of distant recurrence and benefit of adjuvant chemotherapy.4-7,47,48
Referenced with permission from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Breast Cancer V.4.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed July 13, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
ASCO and ESMO are trademarks of the American Society of Clinical Oncology. AJCC is a trademark of the American College of Surgeons. NCCN, ASCO, ESMO, St. Gallen, AGO, and AJCC do not endorse any product or therapy.
-
References
